<abstract xmlns="http://www.w3.org/1999/xhtml"><bold>Introduction. </bold>Despite recent advances in the medical treatment of metastatic colorectal cancer (mCRC), which include oxaliplatinand irinotecan-based first-line regimens and the increasing use of targeted monoclonal antibodies, survival rates for patients with mCRC remain unacceptably low.<bold>Aim of the Study. </bold>Is to analyze survival in patients with unresectable metastatic colorectal cancer.<bold>Materials and Methods. </bold>Retrospective study of unresectable metastatic colorectal cancer patients who underwent palliative chemotherapy in Clinic of Oncology of PaulsStradins Clinical University Hospital from 2004 to 2011was done.<bold>Results.</bold>102 patients had a median PFS of 8 months and median OS of 16 months. Subgroup analysis revealed median PFS of 9 months in the synchronous metastatic disease group and 7 months in the metachronous metastatic disease group (p=0.0089) and median OS of 16 months and 12 months, respectively (p=0.0168).Median OS was 11 months in patients received only one line palliative chemotherapy compared to 19 months in patients received more than one line therapy (p&lt;0.0001).<bold>Conclusions. </bold>The parameter of synchronous and metachronous metastases is of prognostic value in mCRC patients.Second line palliative chemotherapy prolongs overall survival in patient with mCRC.</abstract>

Introduction. Despite recent advances in the medical treatment of metastatic colorectal cancer (mCRC), which include oxaliplatinand irinotecan-based first-line regimens and the increasing use of targeted monoclonal antibodies, survival rates for patients with mCRC remain unacceptably low.Aim of the Study. Is to analyze survival in patients with unresectable metastatic colorectal cancer.Materials and Methods. Retrospective study of unresectable metastatic colorectal cancer patients who underwent palliative chemotherapy in Clinic of Oncology of PaulsStradins Clinical University Hospital from 2004 to 2011was done.Results.102 patients had a median PFS of 8 months and median OS of 16 months. Subgroup analysis revealed median PFS of 9 months in the synchronous metastatic disease group and 7 months in the metachronous metastatic disease group (p=0.0089) and median OS of 16 months and 12 months, respectively (p=0.0168).Median OS was 11 months in patients received only one line palliative chemotherapy compared to 19 months in patients received more than one line therapy (p<0.0001).Conclusions. The parameter of synchronous and metachronous metastases is of prognostic value in mCRC patients.Second line palliative chemotherapy prolongs overall survival in patient with mCRC.

Unresectable Metastatic Colorectal Cancer Treatment and Survival – Pauls Stradins Clinical University Hospital Experience

Institute of Oncology, Riga Stradins University, Latvia

Clinic of Oncology, Pauls Stradins Clinical University Hospital, Pilsoņu Street 13, LV1002, Riga, Latvia

Pauls Stradins Clinical University Hospital, Riga, Latvia

Acta Chirurgica Latviensis

Introduction. Despite recent advances in the medical treatment of metastatic colorectal cancer (mCRC), which include oxaliplatinand irinotecan-based first-line...

Unresectable Metastatic Colorectal Cancer Treatment and Survival – Pauls Stradins Clinical University Hospital Experience

Publicado en línea: 11 may 2013

Páginas: 15 - 19

DOI: https://doi.org/10.2478/v10163-012-0003-y

This content is open access.